Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2017
At a glance
- Drugs BMS 986020 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 18 Jul 2016 Status changed from recruiting to completed.
- 11 Mar 2015 According to the ClinicalTrials.gov record, planned number of patients changed from 300 to 135.
- 14 Mar 2014 Planned End Date changed from 1 Feb 2015 to 1 May 2016, as per ClinicalTrials.gov record.